Lumicell Highlights Growing Role of LumiSystem® as Commercial Expansion Accelerates, including Implementation at Nation’s Leading Cancer Center

Lumicell, Inc., a leader in fluorescence-guided imaging technologies for cancer detection, today highlighted the growing clinical relevance of LumiSystem®, the company’s real-time intraoperative imaging platform for breast-conserving surgery, as Lumicell continues its commercial expansion in the U.S. breast lumpectomy market – including implementation at the nation’s leading cancer center. This momentum underscores Lumicell’s 2026 objectives of scaling LumiSystem in the breast lumpectomy market, driving revenue growth, and increasing access to as many patients as possible. Modern breast cancer care is increasingly moving toward more personalized, de-escalated treatment approaches. As adjuvant therapy is de-escalated, a complete resection at the first operation becomes especially important. Finding residual cancer intraoperatively can support personalization decisions and instill surgical confidence. Unlike specimen-based approaches that evaluate tissue after it has been removed, LumiSystem is designed to interrogate the lumpectomy cavity in situ and show where suspected residual disease remains in the cavity so it can be removed during the same operation. Real-world experience continues to support the clinical relevance of cavity-based imaging, including a recent study out of Stanford Health, titled Performance of Pegulicianine Fluorescence-Guided Evaluation of Lumpectomy Cavities Following Primary Tumor Excision, presented at the American Society of Breast Surgeons (ASBrS) Annual Meeting. “Commercial expansion is about more than broader availability. It is about supporting surgeons with real-time information when it matters most, before the patient leaves the OR,” said Marnie Curbow, Chief Commercial Officer. “As breast cancer treatment becomes more personalized, Lumicell is focused on helping advance breast-conserving surgery with technology designed to detect residual cancer within the lumpectomy cavity during the index procedure. We believe our continued expansion into leading cancer institutions helps accelerate awareness of innovative surgical technologies and expand patient access.” Click here to read more Manage Cookie Consent To provide the best experience, we use technologies such as cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent may adversely affect certain features and functions. Functional Functional Always active The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network. Preferences Preferences The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user. Statistics Statistics The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you. Marketing Marketing The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes. Manage options Manage services Manage {vendor_count} vendors Read more about these purposes Accept Deny View preferences Save preferences View preferences {title} {title} {title} Manage consent

The release as fetched from its publisher. lumicell.com ↗